Masanori Asakura Selected Research

N- (1- ((2,4- diamino- 6- pteridinyl)methyl)- 3,4- dihydro - 2H- 1,4- benzothiazine- 7- carbonyl)- L- 2- aminoadipic acid

4/2004

Methotrexate and MX-68, a new derivative of methotrexate, limit infarct size via adenosine-dependent mechanisms in canine hearts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masanori Asakura Research Topics

Disease

52	Heart Failure 07/2022 - 10/2003
24	Myocardial Infarction 10/2022 - 01/2002
19	Infarction (Infarctions) 10/2018 - 01/2002
16	Reperfusion Injury 12/2017 - 01/2002
12	Cardiomegaly (Heart Hypertrophy) 01/2016 - 01/2002
11	Ischemia 01/2019 - 01/2002
8	Hypertrophy 01/2019 - 09/2002
8	Myocardial Ischemia (Ischemic Heart Diseases) 02/2016 - 07/2002
8	Body Weight (Weight, Body) 12/2012 - 09/2002
7	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 05/2010
7	Fibrosis (Cirrhosis) 01/2020 - 05/2013
7	Diabetes Mellitus 01/2019 - 10/2006
6	Stroke (Strokes) 01/2022 - 01/2011
6	ST Elevation Myocardial Infarction 10/2017 - 01/2014
5	Neoplasms (Cancer) 09/2017 - 03/2002
4	Cardiomyopathies (Cardiomyopathy) 07/2021 - 10/2007
4	Atrial Fibrillation 01/2021 - 04/2017
4	Glucose Intolerance 08/2017 - 10/2006
4	Coronary Occlusion 09/2016 - 01/2002
3	Coronary Artery Disease (Coronary Atherosclerosis) 10/2022 - 10/2018
3	Muscular Dystrophies (Muscular Dystrophy) 01/2022 - 02/2018
3	Chronic Renal Insufficiency 01/2022 - 11/2014
3	Anemia 06/2021 - 11/2017
3	Unstable Angina 01/2021 - 08/2017
3	Left Ventricular Dysfunction 09/2020 - 01/2014
3	Hypoxia (Hypoxemia) 01/2020 - 01/2014
3	Bradycardia 01/2019 - 02/2009
3	Hypertension (High Blood Pressure) 07/2018 - 09/2011
3	Hypotension (Low Blood Pressure) 12/2017 - 10/2007
3	Heart Diseases (Heart Disease) 04/2015 - 01/2011
2	Peripheral Arterial Disease 01/2022 - 05/2021
2	Death (Near-Death Experience) 01/2022 - 04/2015
2	Hypersensitivity (Allergy) 07/2021 - 10/2018
2	Ureteral Obstruction 01/2020 - 07/2018
2	Edema (Dropsy) 01/2019 - 01/2019
2	Inflammation (Inflammations) 10/2018 - 01/2016
2	Type 2 Diabetes Mellitus (MODY) 01/2018 - 05/2010
2	Atherosclerosis 01/2015 - 08/2014

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 03/2016 - 09/2002
10	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 08/2006
8	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2017 - 01/2002
8	Adenosine (Adenocard)FDA LinkGeneric 05/2015 - 01/2002
6	Adenosine Triphosphate (ATP)IBA 02/2015 - 09/2002
5	Pharmaceutical PreparationsIBA 01/2022 - 10/2007
5	Glucose (Dextrose)FDA LinkGeneric 09/2020 - 10/2006
5	AdiponectinIBA 10/2018 - 06/2009
4	Atrial Natriuretic Factor (ANF)IBA 01/2022 - 02/2004
4	tranilastIBA 01/2022 - 01/2018
4	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2019 - 05/2013
4	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 11/2018 - 01/2002
4	Nicorandil (SG 75)IBA 10/2017 - 02/2004
4	CytokinesIBA 09/2017 - 06/2009
4	Purinergic P1 Receptors (Adenosine Receptor)IBA 05/2015 - 01/2002
4	5'-Nucleotidase (5' Nucleotidase)IBA 06/2008 - 09/2003
4	Phosphotransferases (Kinase)IBA 02/2004 - 09/2002
4	NG-Nitroarginine Methyl Ester (L-NAME)IBA 01/2003 - 01/2002
3	Troponin T (Troponin T1)IBA 10/2022 - 02/2004
3	DiureticsIBA 06/2022 - 08/2014
3	Hemoglobins (Hemoglobin)IBA 01/2022 - 07/2019
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2014
3	IronIBA 12/2020 - 11/2017
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2019 - 09/2002
3	Hormones (Hormone)IBA 02/2017 - 05/2013
3	Sodium-Hydrogen ExchangersIBA 04/2016 - 01/2014
3	3- guanidinocarbonyl- 2- methyl- 6,7,8,9- tetrahydro- 5H- cyclohepta(b)pyridine- 9- ylmethyl sulfuric acidIBA 04/2016 - 01/2014
3	Messenger RNA (mRNA)IBA 01/2016 - 03/2010
3	Glucagon-Like Peptide 1 (GLP 1)IBA 05/2015 - 05/2013
3	Histamine (Histamine Dihydrochloride)FDA Link 11/2010 - 05/2006
3	ErbB Receptors (EGF Receptor)IBA 03/2010 - 01/2002
3	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 02/2010 - 01/2002
3	Angiotensin IIIBA 10/2006 - 10/2002
3	Nitric Oxide Synthase (NO Synthase)IBA 08/2004 - 01/2002
3	Endothelin-1 (Endothelin 1)IBA 10/2003 - 10/2002
3	70-kDa Ribosomal Protein S6 Kinases (Ribosomal Protein S6 Kinases, 70 kDa)IBA 04/2003 - 09/2002
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 06/2010
2	evolocumabIBA 10/2022 - 01/2022
2	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 06/2010
2	Creatine Kinase (Creatine Phosphokinase)IBA 01/2022 - 10/2007
2	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2021
2	Eplerenone (Inspra)FDA LinkGeneric 01/2022 - 04/2015
2	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 02/2018
2	SaltsIBA 12/2020 - 01/2019
2	HDL CholesterolIBA 09/2020 - 08/2012
2	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2020 - 04/2009
2	SodiumIBA 01/2020 - 01/2018
2	Transferrin Receptors (Transferrin Receptor)IBA 01/2020 - 01/2019
2	beta Adrenergic ReceptorsIBA 01/2020 - 08/2004
2	VildagliptinIBA 01/2019 - 05/2013
2	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 01/2019 - 05/2013
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2018 - 05/2010
2	human NPPA protein (carperitide)IBA 01/2018 - 08/2014
2	Fibroblast Growth Factor-23IBA 02/2017 - 11/2014
2	Liposomes (Liposome)IBA 01/2016 - 02/2009
2	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 04/2015 - 10/2002
2	AMP-Activated Protein KinasesIBA 01/2015 - 05/2009

Therapy/Procedure

19	Therapeutics 10/2022 - 01/2002
11	Percutaneous Coronary Intervention 10/2022 - 02/2004
4	Patient Readmission 07/2022 - 10/2017
2	Catheter Ablation 01/2019 - 04/2017
2	Secondary Prevention 10/2018 - 05/2010